When Daiichi Sankyo of Japan announced its takeover of Ranbaxy of India this year, the deal raised eyebrows as a rare example of a developer of patented medicines acquiring an aggressive generic drug maker.

If the corporate cultures may be difficult to match, there is a commercial case to be made for innovative drug companies seeking to diversify their product portfolio into off-patent medicines at a time when successful new product development is proving so elusive.